QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)

Horizon Therapeutics Public Stock Price, News & Analysis (NASDAQ:HZNP)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$116.30
$116.30
50-Day Range
$112.60
$116.30
52-Week Range
$60.03
$116.38
Volume
N/A
Average Volume
2.50 million shs
Market Capitalization
$26.63 billion
P/E Ratio
62.19
Dividend Yield
N/A
Price Target
$116.83

Horizon Therapeutics Public MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.5% Upside
$116.83 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
35.08%
From $4.19 to $5.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

842nd out of 949 stocks

Pharmaceutical Preparations Industry

395th out of 435 stocks


HZNP stock logo

About Horizon Therapeutics Public Stock (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.


HZNP Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Rule 17(e) Announcement - Horizon Therapeutics plc
Rule 17(d) Announcement - Horizon Therapeutics plc
Rule 17(d) Announcement – Horizon Therapeutics plc
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Improved Outlook For Horizon Therapeutics And Amgen
Horizon Therapeutics (HZNP) Receives a Hold from H.C. Wainwright
Amgen raises full-year earnings and revenue outlook
See More Headlines
Receive HZNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
11/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:HZNP
CUSIP
44047T10
Employees
2,115
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$116.83
High Stock Price Target
$125.00
Low Stock Price Target
$110.00
Potential Upside/Downside
+0.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$521.48 million
Pretax Margin
12.18%

Debt

Sales & Book Value

Annual Sales
$3.63 billion
Cash Flow
$7.05 per share
Book Value
$22.38 per share

Miscellaneous

Free Float
223,957,000
Market Cap
$26.63 billion
Optionable
Optionable
Beta
1.03

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Should I Buy Horizon Therapeutics Public Stock? HZNP Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Horizon Therapeutics Public was last updated on Tuesday, November 28, 2023 at 1:26 PM.

Pros

Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited:

  • The stock price of Horizon Therapeutics Public Limited has been steadily increasing in recent periods, indicating potential growth and positive investor sentiment.
  • Horizon Therapeutics Public Limited has recently launched a new product, which has received positive reviews and is expected to contribute to the company's revenue growth.
  • The company has a strong financial position, with a healthy balance sheet and positive cash flow, providing stability and potential for future investments and acquisitions.
  • Horizon Therapeutics Public Limited has a diversified product portfolio, reducing the risk associated with relying on a single product or market segment.
  • The company has a robust research and development pipeline, indicating potential for future product innovations and market expansion.

Cons

Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons:

  • The stock price of Horizon Therapeutics Public Limited has experienced volatility in recent periods, which may indicate uncertainty and potential risks for investors.
  • The pharmaceutical industry is highly regulated, and changes in regulations or government policies could impact the company's operations and financial performance.
  • Competition in the pharmaceutical industry is intense, and Horizon Therapeutics Public Limited may face challenges in maintaining market share and pricing power.
  • The company's success is dependent on the successful development and commercialization of its pipeline products, which may involve significant research and development costs and regulatory hurdles.
  • Investing in the stock market always carries inherent risks, and investors should carefully consider their risk tolerance and investment objectives before investing in Horizon Therapeutics Public Limited.














HZNP Stock Analysis - Frequently Asked Questions

Should I buy or sell Horizon Therapeutics Public stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings
or view top-rated stocks.

What is Horizon Therapeutics Public's stock price target for 2024?

7 Wall Street research analysts have issued twelve-month target prices for Horizon Therapeutics Public's stock. Their HZNP share price targets range from $110.00 to $125.00. On average, they predict the company's stock price to reach $116.83 in the next year. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for HZNP
or view top-rated stocks among Wall Street analysts.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. The biopharmaceutical company had revenue of $945 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 20.46% and a net margin of 12.02%. The firm's quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $1.07 EPS.

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a number of institutional and retail investors. Top institutional investors include Pentwater Capital Management LP (0.00%), Walleye Trading LLC (0.00%), Maven Securities LTD (0.00%), Soros Fund Management LLC (1.44%), Adage Capital Partners GP L.L.C. (1.28%) and Morgan Stanley (1.24%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends
.

Does Horizon Therapeutics Public have any subsidiaries?
The following companies are subsidiares of Horizon Therapeutics Public: Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Israel Holding Corp. Ltd, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Services LLC, Horizon Therapeutics Switzerland GmbH, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics, Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, Raptor Pharmaceuticals, River Vision Development Corp., Vidara Therapeutics, and Viela Bio Inc..
Read More
This page (NASDAQ:HZNP) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -